

Supplementary material

Supplementary table 1. Differences in baseline characteristics between patients with and without clinical benefit to checkpoint inhibitors

	Clinical benefit (n=15)	No clinical benefit (n=7)
Age – median (range)	69 (28 – 80)	69 (54 – 77)
Sex – no. (%)		
Male	9 (60)	6 (85.7)
Female	6 (40)	1 (14.3)
ECOG – no. (%)		
0	10 (66.7)	3 (42.9)
1	3 (20)	3 (42.9)
2	2 (13.3)	1 (14.3)
M status – no (%)		
M1a	2 (13.3)	1 (14.3)
M1b	-	-
M1c	11 (73.3)	3 (42.9)
M1d	2 (13.3)	3 (42.9)
Lymph node metastases – no (%)	10 (67.7)	5 (71.4)
Lung metastases – no (%)	10 (66.7)	5 (71.4)
Liver metastases – no . (%)	2 (13.3)	6 (85.7)